Current status of regional arterial infusion chemotherapy.
The rationale for this method is that a prolonged, continuous exposure of tumor cells to an antimetabolite is required for effective antimetabolic activity to develop in the tumor cell population. Overall experience in selected sites such as head and neck, liver, and extremities is reviewed.
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002339:Carotid Arteries; D002404:Catheterization / Q000295:instrumentation; D010478:Chemotherapy, Cancer, Regional Perfusion; D005467:Floxuridine / Q000008:administration & dosage / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006499:Hepatic Artery; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D009062:Mouth Neoplasms / Q000188:drug therapy; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D013699:Temporal Arteries; D013997:Time Factors
D000970:Antineoplastic Agents; D005467:Floxuridine; D005472:Fluorouracil; D008727:Methotrexate